Cargando…
The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity
The poly(ADP-ribose) polymerase (PARP) inhibitor, Rubraca®, was given its first accelerated approval for BRCA-mutated ovarian cancer by the FDA at the end of 2016, and further approval by the FDA, EMA and NICE followed. Scientists at Newcastle University initiated the early stages, and several colla...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139537/ https://www.ncbi.nlm.nih.gov/pubmed/32121331 http://dx.doi.org/10.3390/cancers12030564 |